Literature DB >> 2347045

Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma.

R E Hawkins1, E Wiltshaw, J L Mansi.   

Abstract

Uterine leiomyosarcomas are rare tumours and the results of treatment of advanced disease are poor. Ifosfamide and Adriamycin are both known to be active drugs in soft-tissue sarcomas. We present our experience using ifosfamide alone and in combination with Adriamycin in advanced or recurrent uterine leiomyosarcomas. Ifosfamide alone was given as a 24-h infusion at doses ranging from 5 to 7.5 g/m2, with mesna rescue. In the combination regimen, ifosfamide was given at a dose of 5 g/m2 and Adriamycin, at a dose of 40 or 60 mg/m2. Ten patients were treated with ifosfamide alone, with only one partial response lasting 6 months. In all, 11 patients were treated with ifosfamide and Adriamycin, which resulted in 1 complete response that lasted 11 months. Although many of the patients had extensive disease and some had undergone prior treatment with other chemotherapy, ifosfamide would appear to have only modest activity at the dose and schedule used.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2347045     DOI: 10.1007/bf00685412

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

1.  Prediction of ifosfamide/mesna associated encephalopathy.

Authors:  C A Meanwell; A E Blake; K A Kelly; L Honigsberger; G Blackledge
Journal:  Eur J Cancer Clin Oncol       Date:  1986-07

2.  Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study.

Authors:  R E Slayton; J A Blessing; C Angel; M Berman
Journal:  Cancer Treat Rep       Date:  1987-12

3.  Uterine sarcomas: analysis of failures with special emphasis on the use of adjuvant radiation therapy.

Authors:  O M Salazar; T A Bonfiglio; S F Patten; B E Keller; M L Feldstein; M E Dunne; J H Rudolph
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

4.  Uterine sarcomas: natural history, treatment and prognosis.

Authors:  O M Salazar; T A Bonfiglio; S F Patten; B E Keller; M Feldstein; M E Dunne; J Rudolph
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

5.  Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.

Authors:  E Wiltshaw; G Westbury; C Harmer; A McKinna; C Fisher
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas.

Authors:  V H Bramwell; H T Mouridsen; A Santoro; G Blackledge; R Somers; J Verwey; P Dombernowsky; M Onsrud; D Thomas; R Sylvester
Journal:  Eur J Cancer Clin Oncol       Date:  1987-03

7.  High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.

Authors:  R C Stuart-Harris; P G Harper; C A Parsons; S B Kaye; C A Mooney; N F Gowing; E Wiltshaw
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Sarcomas of the uterine corpus: prognostic factors and treatment.

Authors:  D S Shimm; D A Bell; A F Fuller; M C Bowling; E L Orlow; J E Munzenrider; J H Nelson; F M Ingersoll; N Nikrui; J Donovan
Journal:  Radiother Oncol       Date:  1984-10       Impact factor: 6.280

9.  Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophosphamide.

Authors:  E V Hannigan; R S Freedman; K W Elder; F N Rutledge
Journal:  Gynecol Oncol       Date:  1983-04       Impact factor: 5.482

10.  A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas.

Authors:  G A Omura; F J Major; J A Blessing; T V Sedlacek; J T Thigpen; W T Creasman; R J Zaino
Journal:  Cancer       Date:  1983-08-15       Impact factor: 6.860

View more
  6 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 2.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (malignant mixed mullerian tumors): time for a re-appraisal?

Authors:  Maurie Markman
Journal:  J Cancer Res Clin Oncol       Date:  2004-08-05       Impact factor: 4.553

Review 4.  The role of adjuvant therapy in uterine leiomyosarcoma.

Authors:  Jennifer A Ducie; Mario M Leitao
Journal:  Expert Rev Anticancer Ther       Date:  2015-11-26       Impact factor: 4.512

5.  Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom.

Authors:  Julian F Guest; Erikas Sladkevicius; Nicholas Gough; Mark Linch; Robert Grimer
Journal:  Sarcoma       Date:  2013-03-17

6.  Cost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain, and sweden.

Authors:  Julian F Guest; Monica Panca; Erikas Sladkevicius; Nicholas Gough; Mark Linch
Journal:  Sarcoma       Date:  2013-11-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.